Well done. Thanks for keeping the alphabet soup to a minimum and using language a lay/investor can understand. Also, this was the first someone pieced the history of Leronlimab together in one place so that it can be understood.

My takeaway:

There is so much potential, but patience will be required. Perhaps there will be some short term accomplishment that will move the needle somewhat, but "the billion dollar drug" indications are still in the hands of the FDA.

We need more statistically significant numbers to use LL for the millions of people who need it. The FDA is in a push-pull conundrum. We may get lucky, but luck is not an investment strategy.

If today's PR is more sizzle and no steak, the share price will drop again. OTOH, if steak is served, we can expect reasonable upward movement.